Serum Angiopoietin-1 and Angiopoietin-2 as Biomarkers of Pulmonary Hemodynamic Burden in COPD-Associated Pulmonary Hypertension: A Cross-Sectional Study.
J, B., A, P., MK, A., S, K., AK, V., DK, B., R, S., & M, C. (2026). Serum Angiopoietin-1 and Angiopoietin-2 as Biomarkers of Pulmonary Hemodynamic Burden in COPD-Associated Pulmonary Hypertension: A Cross-Sectional Study.. Advances in respiratory medicine. https://doi.org/10.3390/arm94040059
J B, A P, MK A, S K, AK V, DK B, et al. Serum Angiopoietin-1 and Angiopoietin-2 as Biomarkers of Pulmonary Hemodynamic Burden in COPD-Associated Pulmonary Hypertension: A Cross-Sectional Study.. Advances in respiratory medicine. 2026; doi: 10.3390/arm94040059
J B, A P, MK A, et al. Serum Angiopoietin-1 and Angiopoietin-2 as Biomarkers of Pulmonary Hemodynamic Burden in COPD-Associated Pulmonary Hypertension: A Cross-Sectional Study.[J]. Advances in respiratory medicine. 2026. DOI: 10.3390/arm94040059.
@article{j2026,
author = {Bajpai J and Pradhan A and Ahmad MK and Kant S and Verma AK and Bajaj DK and Sethi R and Cazzola M},
title = {Serum Angiopoietin-1 and Angiopoietin-2 as Biomarkers of Pulmonary Hemodynamic Burden in COPD-Associated Pulmonary Hypertension: A Cross-Sectional Study.},
journal = {Advances in respiratory medicine},
year = {2026},
doi = {10.3390/arm94040059},
note = {PMID: 42644880},
}
TY - JOUR AU - Bajpai J AU - Pradhan A AU - Ahmad MK AU - Kant S AU - Verma AK AU - Bajaj DK AU - Sethi R AU - Cazzola M TI - Serum Angiopoietin-1 and Angiopoietin-2 as Biomarkers of Pulmonary Hemodynamic Burden in COPD-Associated Pulmonary Hypertension: A Cross-Sectional Study. T2 - Advances in respiratory medicine PY - 2026 DO - 10.3390/arm94040059 AN - PMID:42644880 ER -
Purpose: Pulmonary hypertension (PH) is a serious complication of COPD associated with worse outcomes. Reliable circulating biomarkers of pulmonary vascular involvement are lacking. Angiopoietin-1 (ANGP-1) and angiopoietin-2 (ANGP-2) regulate endothelial homeostasis, but their relationship with echocardiographically estimated pulmonary pressure in COPD remains uncertain. Methods: This prospective cross-sectional study included 70 consecutively recruited adults with COPD, stratified using a study-specific echocardiographic threshold into the COPD PH group (mPAP > 20 mmHg; n = 46) and the COPD without PH (mPAP < 20 mmHg; n = 24), together with 20 additional controls. This non-invasive stratification was not considered equivalent to PH confirmed by right heart catheterization. Serum ANGP-1 and ANGP-2 were measured using ELISA. Group differences and associations with e-mPAP and right atrial pressure (RAP) were assessed. Results: Median ANGP-1 was higher in the elevated e-mPAP group [8780.06 (IQR 7955.29-9902.88) pg/mL] than in the lower e-mPAP group [3065.14 (1170.69-6200.41)] and controls [2997.19 (1292.13-3278.18); p < 0.001]. ANGP-2 showed a similar pattern [6152.92 (5380.27-8652.50), 2669.77 (1802.18-4744.00), and 2405.54 (1779.73-3751.76) pg/mL; p < 0.001]. Among COPD participants, ANGP-1 and ANGP-2 correlated with e-mPAP (r = 0.64 and r = 0.54) and RAP (r = 0.54 and r = 0.52; all Holm-adjusted p < 0.001). In multivariable models, e-mPAP and RAP were independently associated with ANGP-1, whereas RAP was independently associated with ANGP-2. Conclusions: Higher circulating ANGP-1 and ANGP-2 were associated with an elevated echo-estimated pulmonary-pressure phenotype in COPD. These findings are exploratory and require validation in larger cohorts using direct hemodynamic assessment.